Comparison of Clinical Features and Survival between Cryptococcosis in Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Patients
|
|
- Iris Glenn
- 5 years ago
- Views:
Transcription
1 Jpn. J. Infect. Dis., 61, , 2008 Original Article Comparison of Clinical Features and Survival between Cryptococcosis in Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Patients Ubonvan Jongwutiwes, Somnuek Sungkanuparph and Sasisopin Kiertiburanakul* Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (Received June 27, Accepted December 28, 2007) SUMMARY: Cryptococcosis is a life-threatening fungal infection among human immunodeficiency virus (HIV)- positive patients and also occurs frequently in HIV-negative patients. A retrospective cohort study was conducted among patients with cryptococcosis. Clinical manifestations, laboratory findings, treatment, and outcomes for 149 HIV-positive and 29 HIV-negative patients were compared. Neurological involvement occurred more frequently in HIV-positive patients (91.9 versus 20.7%, P < 0.001), whereas pulmonary involvement was more frequently observed in HIV-negative patients (34.5 versus 2.7%, P < 0.001). Ninety percent of HIV-positive patients and 74% of HIV-negative patients had positive serum cryptococcal antigen (P = 0.119). HIV-positive patients were more likely to have a cerebrospinal fluid (CSF) preparation that is positive for India ink staining (81 versus 50%, P < 0.001) and a CSF cryptococcal antigen titer of 1:1,024 (61.1 versus 16.7%, P = 0.038). Most of the patients in both groups received amphotericin B as the primary therapy. Cryptococcosis-related mortality was high and did not differ between the two groups (22.2 versus 34.5%, P = 0.162). Kaplan-Meier analysis revealed that HIVpositive patients had a higher relapse rate (P = 0.011), especially among those lacking antiretroviral therapy. In conclusion, the clinical presentation of cryptococcosis among HIV-negative patients varies and differs from that of HIV-positive patients. Awareness and prompt management are crucial for establishing a diagnosis and initiating proper treatment. INTRODUCTION Cryptococcosis is a systemic infection caused by Cryptococcus neoformans, a yeast that can be isolated from the environment. C. neoformans causes human diseases ranging from asymptomatic pulmonary colonization to meningitis and disseminated infection. Cryptococcosis is seen in apparently normal hosts as well as in immunocompromised hosts such as patients with hematologic malignancy, organ transplant, rheumatic disease, and those receiving immunosuppressive therapy (1,2). Cryptococcosis is also one of the most common opportunistic fungal infections in patients with acquired immunodeficiency syndrome (AIDS), and in this subgroup, infection is associated with high morbidity and mortality (3). The natural history of cryptococcal infection in patients with AIDS in the pre-highly active antiretroviral therapy (HAART) era has been well documented in many studies (4-8). In addition, the clinical characteristics and natural history of cryptococcosis in human immunodeficiency virus (HIV)- negative patients have been described in the literature (9-15). Some reports differ with regard to cryptococcosis infection in HIV-negative and HIV-positive patients (13,16). To date, few studies have reported comparative data regarding the clinical manifestations, laboratory findings, and survival of HIV-positive and HIV-negative patients, especially those affected during the HAART era. Information about similarities and differences between the two populations with respect to clinical features and survival rates may be useful for the recognition, diagnosis, and management of cryptococcosis in clinical practice. Here, we aimed to compare the clinical *Corresponding author: Mailing address: Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Rama 6 Road, Bangkok 10400, Thailand. Tel: , Fax: , rasal@mahidol.ac.th features and survival associated with cryptococcal infections in these two groups of patients. PATIENTS AND METHODS A retrospective cohort study was conducted by reviewing the medical records of adult patients ( 15 years old) who were diagnosed with cryptococcal infection at Ramathibodi Hospital (an 800-bed medical school hospital in Bangkok, Thailand) from January 1996 through December Patients were categorized into two groups according to the anti-hiv antibody seropositivity. The reviewed data included clinical manifestations, underlying conditions, laboratory findings, treatment, survival, and treatment outcomes. In addition, information about the following were retrieved for the HIVpositive group: treatment with an antiretroviral therapy (ART) regimen, CD4 cell count, and HIV RNA levels. The diagnosis of cryptococcosis was based on one or more of the following: a positive culture, a positive histopathological study, a positive India ink preparation of the cerebrospinal fluid (CSF), or a positive serum cryptococcal antigen titer. Disseminated infection was defined by the presence of a positive culture for C. neoformans from more than one site, or a positive culture for C. neoformans from one site (other than from a blood sample) plus a positive test for serum cryptococcal antigen. All available patient records were reviewed from the time of cryptococcal diagnosis until the patients died or were lost to follow up, or until the end of the study on 31 December The clinical features, laboratory findings, treatment, and outcomes (including survival) for the two groups of patients were compared. Factors that would predict a poor outcome were also evaluated. The duration of follow-up was measured from the time of cryptococcal diagnosis to the date of the last visit or the date on which a primary end point was reached. The primary end point of the study was death from 111
2 cryptococcosis. Secondary end points were a confirmed diagnosis of relapse of cryptococcal disease. Relapse was defined as a culture-positive condition with or without clinical disease or clinical evidence of relapse with histopathological confirmation. The study protocol was approved by the Institutional Review Board. Statistical analysis: Categorical data are presented as the median and range. Continuous data are expressed either as the mean and standard deviation (SD) or median and range based on the distribution. Categorical variables were compared by using the 2 test or Fisher s exact test (two-tailed), depending on which was appropriate. Numerical variables were compared using Student s t test or the Mann-Whitney rank-sum test based on the distribution. Patients who had at least one follow-up evaluation after diagnosis were included in the survival analysis. Kaplan-Meier survival analysis with the log-rank test was used to compare the two groups in terms of time-to-relapse and time-to-death due to cryptococcosis. Cox s proportional hazard regression analysis was carried out to identify the factors associated with relapse and death. All analyses were performed by using SPSS statistical software version A P-value of <0.05 was considered statistically significant. RESULTS During the 10-year period between 1996 and 2005, there were 178 patients diagnosed with cryptococcal infection. Of these, 149 (83.7%) patients were HIV-positive. A comparison of the clinical features of HIV-positive and HIV-negative patients is shown in Table 1. HIV-positive patients had cryptococcal infection at a younger age than HIV-negative patients (32 versus 44 years, P < 0.001). According to the site of infection, HIV-positive patients were more likely to have central nervous system (CNS) involvement (91.7 versus 21.7%, P < 0.001), while HIV-negative patients were more likely to have pulmonary cryptococcosis (34.5 versus 2.7%, P < 0.001). Disseminated infection was found in approximately half of the subjects in both groups. There was a trend toward a higher frequency of positive serum cryptococcal antigen test in the HIV-positive patients, but this difference was not significantly different (90.3 versus 73.7%, P = 0.119). For HIV-positive patients, the median CD4 cell count was 22 (interquartile range, 5-71) cells/mm 3. Cryptococcosis was an initial AIDS-defining illness in 77 (51.7%) patients. Of the HIV-negative patients, 20 (69%) had associated illnesses, 15 (51.7%) received immunosuppressive therapy, 7 (24.1%) had systemic lupus erythematosus, 6 (20.7%) had malignancies, 3 (10.3%) had diabetes mellitus, 2 (6.9%) had chronic inflammatory demyelinating disease, 2 (6.9%) had cirrhosis, and 6 (20.7%) patients had other conditions. CSF findings for the 137 HIV-positive patients and 6 HIVnegative patients with meningitis are shown in Table 2. There was a higher median CSF leukocyte count among HIVnegative patients than HIV-positive patients, but the difference was not statistically significant. HIV-positive patients Table 1. Clinical and laboratory findings among HIV-positive and HIV-negative patients with cryptococcosis Characteristics No. of HIV-positive (%) No. of HIV-negative (%) (n = 149) (n = 29) P value Male gender 85 (57) 9 (31) Median age, years (range) 32 (20-64) 44 (16-83) <0.001 Type of infection Localized infection 87 (58.4) 14 (48.3) Disseminated infection 62 (41.6) 15 (51.7) Site of localized infection <0.001 Meningitis 84 (96.6) 3 (21.4) Lymph node 1 (1.1) 1 (7.1) Lung 2 (2.3) 5 (35.7) Bone and joint 0 2 (14.3) Others 0 3 (21.4) 1) Pulmonary involvement 4 (2.7) 10 (34.5) <0.001 CNS involvement 137 (91.9) 6 (20.7) <0.001 Positive serum cryptococcal antigen 65/72 (90.3) 14/19 (73.7) Positive hemoculture for C. neoformans 58 (38.9) 11 (37.9) ) : Gastrointestinal tract, peritoneum and scalp. CNS, central nervous system. Table 2. CSF findings of patients with cryptococcal meningitis CSF findings No. of HIV-positive (%) No. of HIV-negative (%) (n = 137) (n = 6) P value Median open pressure, cmh 2 O (range) 25 (5-60) 25.5 (8-58) Median leukocyte, cells/mm 3 (range) 10 (0-900) 89 (0-165) Median protein, g/l (range) 60.5 (10-495) 104 (28-136) Median glucose, g/l (range) 45 (11-160) 34.5 (25-138) Positive CSF culture 115 (83.9) 4 (33.3) Positive India ink preparation 111 (81) 3 (50) <0.001 Positive cryptococcal antigen 86/99 (86.9) 5 (83.3) Cryptococcal antigen titer 1: /72 (61.1) 1 (16.7) CSF, cerebrospinal fluid. 112
3 Fig. 1. Kaplan-Meier survival curve demonstrating survival from cryptococcal-related mortality for HIV-positive and HIV-negative patients. Fig. 2. Kaplan-Meier survival curves demonstrating probability of free from relapse of cryptococcosis in HIV-positive patients with and without antiretroviral therapy (ART) and HIV-negative patients. were more likely to have positive results on India ink preparation of the CSF (81.0 versus 50.0%, P < 0.001). Although the CSF cryptococcal antigen was positive in >80% of patients in both groups (P = 0.558), HIV-positive patients were more likely to have a CSF cryptococcal antigen titer of 1:1,024 (61.1 versus 16.7%, P = 0.038). There was no statistically significant difference between the two groups in terms of open pressure, protein level, glucose level, or positive CSF culture. The mainstay of treatment in both groups was amphotericin B. Of the HIV-positive patients, 120 (80.5%) were initially treated with an amphotericin B-based regimen, and 29 (19.5%) received a non-amphotericin B-based regimen including fluconazole (17 patients), liposomal nystatin (9 patients), and itraconazole (3 patients). Of the HIV-negative patients, 21 (72.4%) were initially treated with an amphotericin B- based regimen, and 4 (13.8%) were treated with fluconazole. The median cumulative dose of amphotericin B in these HIVnegative patients was 800 mg (range 40-4,000 mg) and the median duration of oral fluconazole treatment was 90 days (range 15-1,080 days). Four (13.8%) patients did not receive any antifungal drugs because they were initially misdiagnosed. Overall cryptococcal-related mortality was 24.2%. The cryptococcal-related mortality did not differ significantly between groups (22.2 versus 34.5%, P = 0.162). The Kaplan- Meier survival curve demonstrating survival for cryptococcalrelated mortality is shown in Figure 1. The median survival duration of HIV-positive patients and HIV-negative patients was >59.9 and >67.9 months, respectively (P = 0.428). Seventy-five-percent survival durations for the corresponding groups were 15.2 and 2.1 months, respectively. The overall relapse rate was 19.1%. The relapse rates in HIV-positive patients with ART, HIV-positive patients without ART, and HIV-negative patients were 13.5% (7 of 52 patients), 24.7% (24 of 97 patients), and 10.3% (3 of 29 patients), respectively. The Kaplan-Meier survival curve demonstrating relapse-free survival for HIV-positive and HIVnegative patients is shown in Figure 2. The median survival (free) from relapse duration was 49.1 months in the HIVpositive group and >67.9 months in the HIV-negative group (P = 0.011). Moreover, there was a statistically significant difference in relapse-free survival between HIV-positive patients who did not receive ART and that of the other two groups (P < 0.001) (Figure 2). Cox s regression demonstrated that the only significant risk factor for a relapse of cryptococcal infection was HIV infection (hazard ratio [HR] 5.83; 95% confidence interval [CI] , P = 0.034). Male gender (HR 0.51; 95% CI ; P = 0.071), age (HR 0.96; 95% CI ; P = 0.064), CNS involvement (HR 0.65; 95% CI ; P = 0.427), and pulmonary involvement (HR 2.31; 95% CI ; P = 0.327) were not risk factors. DISCUSSION In the course of the AIDS epidemic, cryptococcosis has been one of the major AIDS-defining illnesses in HIV-infected patients (17). The decreasing incidence of cryptococcosis among HIV-infected patients has been documented after the introduction of ART. In contrast, a slight increase in cryptococcosis in HIV-negative patients has been observed due to the increased use of immunosuppressive therapy. An underlying immunosuppressed condition was identified in the majority of our patients. However, approximately one-third of our patients had no known underlying medical condition. These data are similar to findings from a previous study (14). To the best of our knowledge, the present study is among the larger-scale cohort studies of cryptococcosis, especially with respect to comparisons between these two particular groups of patients. Our main observations were that cryptococcal meningitis occurred more commonly in HIV-positive patients, but pulmonary involvement was found more frequently in HIVnegative patients. According to the largest reported study of cryptococcosis in HIV-negative patients, pulmonary involvement and CNS involvement was found in 36 and 51% of patients, respectively (14). The organism is trophic to the CNS, and the majority of cases have been found to be meningitis. 113
4 As the site of entry, the respiratory tract is the most frequently involved among the organ systems when cryptococcal infection develops (18,19). In animal models, the role of immune status and an organism s particular ability to induce a pulmonary inflammatory response may establish the course of clinical features (20). For example, C. neoformans may remain primary in the lung or may undergo hematogenous spread to other systems (16). Meningitis was found in a fewer number of HIV-negative than HIV-positive patients in the present study. This difference may be due to the lower proportion of patients (58.6%) who underwent lumbar puncture comparing with that of the HIV-positive group (96.6%). Asymptomatic meningitis can develop in patients with T-cell suppression and it may also be under-recognized (10). Although it was recommended in the year 2000 that all patients with cryptococcal disease undergo lumbar puncture (21), this procedure had not been routinely performed in earlier years. According to the CSF findings in patients with meningitis, the mean open intracranial pressure was high (>20 mmh 2 O) in both groups. This finding is similar to those of previous studies of Thai patients (13,22). In the present study, a higher proportion of HIV-positive patients tested positive on India ink preparation and had high titers of cryptococcal antigen in the CSF. Although, there was a trend toward higher CSF pleocytosis among HIV-negative patients, the difference was not statistically significant. No other between-group differences in the CSF findings were observed. The diagnosis of cryptococcosis in HIV-negative patients is thus rather difficult and warrants an aggressive procedure to establish diagnosis. The choice of therapy for cryptococcosis depends on both the site(s) of involvement and the host s immune status. Amphotericin B plus flucytosine followed by fluconazole is preferred for the treatment of CNS infection and for patients with severe symptoms (21). Fluconazole is recommended for patients with pulmonary disease (21). The regimens for treatment in the present study were heterogeneous secondary to a long study period. Flucytosine has not been available in Thailand for at least 10 years, and some patients in the study received liposomal nystatin, an investigational drug. However, most of the patients in both groups received amphotericin B as the initial treatment. The mortality rate was high in both groups, and no statistically significant difference (22.2 and 34.5%) was observed between them in this regard. This high rate is concordant with rates of 25-30% reported in previous studies (2,10,11,23). We found that both groups had a high relapse rate. HIVpositive patients without ART had the highest relapse rate. The relapse rate was previously reported as 2-43%, depending on patient characteristics and treatment regimens (17, 24,25). Several factors may have attributed to the relapse rate. Differences in the following factors could have confounded the results: initial treatment regimen, availability of secondary prophylaxis, and access to ART. The present study clearly demonstrated that HIV infection was a significant risk for relapse of cryptococcosis, i.e., HIV-infected patients were sixfold more likely to have a relapse than patients not infected with HIV. However, it is difficult to arrive at a definitive conclusion, as patient compliance with treatment could not be assessed. The present study had a number of limitations. First, this was a retrospective study with a small number of HIVnegative cases collected over a long period of time. Patients with cryptococcosis who had been diagnosed and treated more recently may have had better outcomes secondary to improvement in diagnosis and increased options among better antifungal agents in recent years. However, there were no differences in clinical features and outcomes between HIVinfected patients who had cryptococcosis before and after the year 2000 (data not shown). Unfortunately, due to the small sample, this analysis was not feasible in the group of HIVnegative patients. Second, because this was a retrospective study, there were missing data regarding the CSF findings. Third, a variety of C. neoformans was not identified, which might have had an impact on outcomes due to differences in the distribution of the gattii and neoformans varieties in nonimmunosuppressed and immunosuppressed populations (26). Lastly, a higher number of HIV-positive patients was included in the study due to the high prevalence of HIV infection in Thailand, and cryptococcosis is the third-most common AIDSdefining illness among Thai patients (27). An inappropriate proportion of HIV-positive versus HIV-negative patients for the analysis may have yielded a lack of statistical significant difference for some variables. In summary, due to a high mortality rate, cryptococcosis is a threatening infectious disease in both HIV-positive and HIVnegative patients. Cryptococcal-related mortality was found to be comparable between HIV-positive and HIV-negative patients. The results of the present study provided substantial information or differentiating between HIV-positive and HIVnegative patients based on clinical features, laboratory findings, and cryptococcosis outcomes. ART was found to be an important factor associated with a lower relapse rate in HIV-infected patients and it should be administered to HIVinfected patients with cryptococcosis. ACKNOWLEDGMENTS The authors would like to thank the staff of the Department of Medicine and Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, for taking care of patients and their kind cooperation in data collection. Assistance from the medical chart service staff is duly noted. We also thank Professor Amnuay Thithapandha for constructive suggestions and English editing. The abstract of this study was presented as a poster at the 8th International Congress on Drug Therapy in HIV Infection, Glasgow, 2006 (abstract P333). REFERENCES 1. Ennis, D.M. and Saag, M.S. (1993): Cryptococcal meningitis AIDS. Hosp. Pract. (Off Ed), 28, , , Diamond, R.D. and Bennett, J.E. (1974): Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann. Intern. Med., 80, Mitchell, T.G. and Perfect, J.R. (1995): Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev., 8, Antinori, S., Galimberti, L., Magni, C., et al. (2001): Cryptococcus neoformans infection in a cohort of Italian AIDS patients: natural history, early prognostic parameters, and autopsy findings. Eur. J. Clin. Microbiol. Infect. Dis., 20, French, N., Gray, K., Watera, C., et al. (2002): Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS, 16, Grant, A.D., Djomand, G. and De Cock, K.M. (1997): Natural history and spectrum of disease in adults with HIV/AIDS in Africa. AIDS, 11, S Mwaba, P., Mwansa, J., Chintu, C., et al. (2001): Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad. Med. J., 77, Darras-Joly, C., Chevret, S., Wolff, M., et al. (1996): Cryptococcus neoformans infection in France: epidemiologic features of and early prognostic parameters for 76 patients who were infected with human immunodeficiency virus. Clin. Infect. Dis., 23,
5 9. Pasqualotto, A.C., Bittencourt Severo, C., de Mattos Oliveira, F., et al. (2004): Cryptococcemia. An analysis of 28 cases with emphasis on the clinical outcome and its etiologic agent. Rev. Iberoam. Micol., 21, Kiertiburanakul, S., Wirojtananugoon, S., Pracharktam, R., et al. (2006): Cryptococcosis in human immunodeficiency virus-negative patients. Int. J. Infect. Dis., 10, Shih, C.C., Chen, Y.C., Chang, S.C., et al. (2000): Cryptococcal meningitis in non-hiv-infected patients. Q. J. Med., 93, Moosa, M.Y. and Coovadia, Y.M. (1997): Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients. Clin. Infect. Dis., 24, Viriyavejakul, P., Tangwanicharoen, T., Punpoowong, B., et al. (2004): Cryptococcal meningitis in human immunodeficiency virus (HIV)- positive and HIV-negative patients. Southeast. Asian J. Trop. Med. Public Health, 35, Pappas, P.G., Perfect, J.R., Cloud, G.A., et al. (2001): Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin. Infect. Dis., 33, Lu, C.H., Chang, W.N., Chang, H.W., et al. (1999): The prognostic factors of cryptococcal meningitis in HIV-negative patients. J. Hosp. Infect., 42, Chang, W.C., Tzao, C., Hsu, H.H., et al. (2006): Pulmonary cryptococcosis: comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients. Chest, 129, Saag, M.S. (1995): Editorial response: clinical and host difference between infection with the two varieties of Cryptococcus neoformans. Clin. Infect. Dis., 21, Woodring, J.H., Ciporkin, G., Lee, C., et al. (1996): Pulmonary cryptococcosis. Semin. Roentgenol., 31, Sider, L. and Westcott, M.A. (1994): Pulmonary manifestations of cryptococcosis in patients with AIDS: CT features. J. Thorac. Imaging, 9, Curtis, J.L., Huffnagle, G.B., Chen, G.H., et al. (1994): Experimental murine pulmonary cryptococcosis. Differences in pulmonary inflammation and lymphocyte recruitment induced by two encapsulated strains of Cryptococcus neoformans. Lab. Invest., 71, Saag, M.S., Graybill, R.J., Larsen, R.A., et al. (2000): Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis., 30, Tunlayadechanont, S., Viranuvatti, K., Phuapradit, P., et al. (1997): Cryptococcal meningitis in patients with non-hiv and HIV infection: a clinical study. Neurol. J. Southeast. Asia, 2, Jean, S.S., Fang, C.T., Shau, W.Y., et al. (2002): Cryptococcaemia: clinical features and prognostic factors. Q. J. M., 95, Speed, B. and Dunt, D. (1995): Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin. Infect. Dis., 21, Saag, M.S., Cloud, G.A., Graybill, J.R., et al. (1999): A comparison of itraconazole versus fluconazole as maintenance therapy for AIDSassociated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin. Infect. Dis., 28, Rozenbaum, R. and Gonçalves, A.J. (1994): Clinical epidemiological study of 171 cases of cryptococcosis. Clin. Infect. Dis., 18, Epidemiological Information Section, Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health: AIDS situation in Thailand up to March 31, Online at < epi32_aids.html>. Accessed April 9,
Original Article. Noparat Oniem, M.D., Somnuek Sungkanuparph, M.D.
Original Article Vol. 29 No. 1 Primary prophylaxis for cryptococcosis with fluconazole:- Oniem N & Sungkanuparph S. 5 Primary prophylaxis for cryptococcosis with fluconazole among HIV-infected patients
More informationCryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease
Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol
More informationTe-Yu Lin, Kuo-Ming Yeh, Jung-Chung Lin, Ning-Chi Wang, Ming-Yieh Peng, Feng-Yee Chang
J Microbiol Immunol Infect. 9;:-6 Cryptococcal disease in patients with or without human immunodeficiency virus: clinical presentation and monitoring of serum cryptococcal antigen titers Te-Yu Lin, Kuo-Ming
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01367.x Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated
More informationCryptococcal meningitis in HIV-infected patients: a longitudinal study in Cambodia
Tropical Medicine and International Health doi:10.1111/j.1365-3156.2010.02622.x volume 15 no 11 pp 1375 1381 november 2010 Cryptococcal meningitis in HIV-infected patients: a longitudinal study in Cambodia
More informationRAPIDLY PROGRESSIVE PULMONARY CRYPTOCOCCOSIS WITH CAVITATION IN AN IMMUNOCOMPETENT WOMAN: A CASE REPORT AND LITERATURE REVIEW
RAPIDLY PROGRESSIVE PULMONARY CRYPTOCOCCOSIS WITH CAVITATION IN AN IMMUNOCOMPETENT WOMAN: A CASE REPORT AND LITERATURE REVIEW Junyan Qu, Xiaohui Wang, Yanbin Liu and Xiaoju Lv Center of Infectious Disease,
More informationManagement of Cryptococcal Meningitis in HIV-infected children in National Pediatric Hospital
Management of Cryptococcal Meningitis in HIV-infected children in National Pediatric Hospital Olivier Marcy 1,2, Sam Sophan 2, Ung Vibol 2, Chan Bunthy 2, Pok Moroun 2, Chy Kam Hoy 2, Ban Thy 2, Chhour
More informationComparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection
Journal of Microbiology, Immunology and Infection (2011) 44, 338e345 available at www.sciencedirect.com journal homepage: www.e-jmii.com ORIGINAL ARTICLE Comparisons of clinical features and mortality
More informationChallenges in Management of Cryptococcal Meningitis. Yunus Moosa Department of ID NRMSM Durban
Challenges in Management of Cryptococcal Meningitis Yunus Moosa Department of ID NRMSM Durban Overview Epidemiology Pathogenesis Clinical presentation Diagnosis Prognostic factors Antifungal Treatment
More informationKAP conference 19 th March 2008: Dr Mohamed Hussein Jin.
SENSITIVITY PATTERNS, SEROTYPES OF CRYPTOCOCCUS NEOFORMANS AND DIAGNOSTIC VALUE OF INDIA INK IN PATIENTS WITH CRYPTOCOCCAL MENINGITIS AT KENYATTA NATIONAL HOSPITAL. KAP conference 19 th March 2008: Dr
More informationJudith A. Aberg, MD; Linda M. Mundy, MD; and William G. Powderly, MD
Pulmonary Cryptococcosis in Patients Without HIV Infection* Judith A. Aberg, MD; Linda M. Mundy, MD; and William G. Powderly, MD Purpose: To further elucidate the diagnostic and therapeutic approaches
More informationCRYPTOCOCCOSIS IN HIV-INFECTED CHILDREN
CRYPTOCOCCOSIS IN HIV-INFECTED CHILDREN Surachai Likasitwattanakul, Boonsom Poneprasert and Virat Sirisanthana Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
More informationCRYPTOCOCCAL MENINGITIS IN HIV-INFECTED PATIENTS AT CHIANG MAI UNIVERSITY HOSPITAL: A RETROSPECTIVE STUDY
CRYPTOCOCCAL MENINGITIS IN HIV-INFECTED PATIENTS AT CHIANG MAI UNIVERSITY HOSPITAL: A RETROSPECTIVE STUDY Romanee Chaiwarith 1, Surachet Vongsanim 1 and Khuanchai Supparatpinyo 1, 2 1 Department of Medicine,
More informationISPUB.COM. Cryptococcal Meningitis in AIDS. O Busari, A Adeyemi, S Agboola INTRODUCTION BIOLOGY AND PATHOGENESIS CLINICAL FEATURES
ISPUB.COM The Internet Journal of Infectious Diseases Volume 7 Number 1 O Busari, A Adeyemi, S Agboola Citation O Busari, A Adeyemi, S Agboola.. The Internet Journal of Infectious Diseases. 2008 Volume
More informationGUIDELINE FOR THE MANAGEMENT OF CRYPTOCOCCAL MENINGITIS
GUIDELINE FOR THE MANAGEMENT OF CRYPTOCOCCAL MENINGITIS Full title of guideline Guideline for the management of cryptococcal meningitis Author Dr P Venkatesan (ID consultant) Division and specialty Medicine,
More informationApatcha Pungjitprapai, M.D., Mattana Hanvanich, M.D. Abstract of Infectious Diseases Fellows
of Infectious Diseases Fellows A Study of Plasma HIV RNA Viral Load Response to the Treatment with Low Dose Stavudine (D4T) in Lamivudine (3TC) and Efavirenz Containing Highly Active Antiretroviral Regimen
More informationCryptococcal Meningitis: Looking beyond HIV
International Journal of Scientific and Research Publications, Volume 3, Issue 3, March 2013 1 Cryptococcal Meningitis: Looking beyond HIV Deepak Nayak M *. Sushma V. Belurkar **, Chethan Manohar ***,
More informationClinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America
IDSA GUIDELINES Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America John R. Perfect, 1 William E. Dismukes, 2 Francoise Dromer,
More informationCryptococcal Meningitis
Cryptococcal Meningitis Dr N Thumbiran Infectious Diseases Department UKZN Index patient 27 year old female Presented to King Edward Hospital on 17/07/2005 with: Severe headaches Vomiting Photophobia X
More informationORIGINAL ARTICLE STUDY OF CRYPTOCOCCAL MENINGITIS IN HIV POSITIVE PATIENTS
STUDY OF CRYPTOCOCCAL MENINGITIS IN HIV POSITIVE PATIENTS Sunil Kumar 1, Madhu Jumla. 1. Assistant Professor, Department of Medicine, Vijayanagara Institute of Medical Sciences, Bellary, Karnataka.. Assistant
More informationCommon Fungi. Catherine Diamond MD MPH
Common Fungi Catherine Diamond MD MPH Birth Month and Day & Last Four Digits of Your Cell Phone # BEFORE: http://tinyurl.com/kvfy3ts AFTER: http://tinyurl.com/lc4dzwr Clinically Common Fungi Yeast Mold
More informationPractice Guidelines for the Management of Cryptococcal Disease
Subscription Information for 710 Practice Guidelines for the Management of Cryptococcal Disease Michael S. Saag, 1 Richard J. Graybill, 2 Robert A. Larsen, 3 Peter G. Pappas, 1 John R. Perfect, 4 William
More informationCase Report Diagnosis of Cryptococcosis and Prevention of Cryptococcal Meningitis Using a Novel Point-of-Care Lateral Flow Assay
Case Reports in Medicine Volume 2013, Article ID 640216, 4 pages http://dx.doi.org/10.1155/2013/640216 Case Report Diagnosis of Cryptococcosis and Prevention of Cryptococcal Meningitis Using a Novel Point-of-Care
More informationMonitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients
DOI: 10.1111/j.1468-1293.2009.00778.x HIV Medicine (2010), 11, 276 281 ORIGINAL RESEARCH r 2009 British HIV Association Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration
More informationThe availability and cost are obstacles to using pvl in monitoring HIV treatment outcomes in resource-constrained settings
Impact of the frequency of plasma viral load monitoring on treatment outcome among perinatally HIVinfected Asian children stable on first-line NNRTI-based cart T Sudjaritruk, DC Boettiger, NV Lam, KAM
More informationCryptococcal Meningitis in Patients with or without Human Immunodeficiency Virus: Experience in a Tertiary Hospital
Original Article DOI 10.3349/ymj.2011.52.3.482 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 52(3):482-487, 2011 Cryptococcal Meningitis in Patients with or without Human Immunodeficiency Virus: Experience
More informationECMM Excellence Centers Quality Audit
ECMM Excellence Centers Quality Audit Person in charge: Department: Head of Department: Laboratory is accredited according to ISO 15189 (Medical Laboratories Requirements for quality and competence) Inspected
More informationDifferent presentations and outcomes between HIV-infected and HIV-uninfected patients with Cryptococcal meningitis
Journal of Microbiology, Immunology and Infection (2012) 45, 296e304 Available online at www.sciencedirect.com journal homepage: www.e-jmii.com ORIGINAL ARTICLE Different presentations and outcomes between
More informationDisseminated cryptococcosis in Crohn s disease: a case report
Chavapradit and Angkasekwinai BMC Infectious Diseases (2018) 18:620 https://doi.org/10.1186/s12879-018-3553-3 CASE REPORT Open Access Disseminated cryptococcosis in Crohn s disease: a case report Natthakit
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More informationCRYPTOCOCCUS MENINGITIS IN A COHORT OF HIV POSITIVE KENYAN PATIENTS: OUTCOME AFTER TWO WEEKS OF THERAPY
December 2013 (Supplement) Ea s t Af r i c a n Me d i c a l Jo u r n a l S33 East African Medical Journal Vol. 90 No. 12 (Supplement) December 2013 CRYPTOCOCCUS MENINGITIS IN A COHORT OF HIV POSITIVE KENYAN
More informationFungal Meningitis. Stefan Zimmerli Institute for infectious diseases University of Bern Friedbühlstrasse Bern
Fungal Meningitis Stefan Zimmerli Institute for infectious diseases University of Bern Friedbühlstrasse 51 3010 Bern Death due to infectious diseases in sub-saharan Africa Park BJ. Et al AIDS 2009;23:525
More informationGAFFI Fact Sheet. Cryptococcal meningitis. Introduction
GAFFI Fact Sheet Cryptococcal meningitis ION NS ACT ALOR ECTIO B GLOND F L INF FU NGA FU Introduction DARKER AREAS AND TEXT FIT WITHIN CIRCLE Cryptococcal meningitis is caused by one of the two closely
More informationFungal Meningitis in an Immunocompetent Patient
Clin Drug Investig (2013) 33 (Suppl 1):S47 S50 DOI 10.1007/s40261-012-0021-5 CASE REPORT Fungal Meningitis in an Immunocompetent Patient Ricardo Louro Rui Ferreira Catarina Pinheiro Helena Parada Domitília
More informationDisseminated Cryptococcosis with Adrenal Insufficiency and Meningitis in an Immunocompetent Individual
CASE REPORT Disseminated Cryptococcosis with Adrenal Insufficiency and Meningitis in an Immunocompetent Individual Misa Ito 1, Takashi Hinata 1, Kaku Tamura 1, Ayano Koga 2, Toshimitsu Ito 1, Hiroko Fujii
More informationIntegrated therapy for HIV and cryptococcosis
Srichatrapimuk and Sungkanuparph AIDS Res Ther (2016) 13:42 DOI 10.1186/s12981-016-0126-7 AIDS Research and Therapy REVIEW Open Access Integrated therapy for HIV and cryptococcosis Sirawat Srichatrapimuk
More informationPREVALENCE OF CRYPTOCOCCAL MENINGITIS AMONGST HIV SEROPOSITIVE CASES FROM A TERTIARY CARE HOSPITAL
IJCRR Vol 06 issue 14 Section: Healthcare Category: Research Received on: 25/05/14 Revised on: 21/06/14 Accepted on: 12/07/14 PREVALENCE OF CRYPTOCOCCAL MENINGITIS AMONGST HIV SEROPOSITIVE CASES FROM A
More informationMeningi&s in HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Meningi&s in HIV Christina M. Marra, MD Neurology and Medicine University of Washington School of Medicine Susceptibility to CNS Opportunistic Infections CD4+
More informationHISTOPLASMOSIS - LABORATORY DIAGNOSIS IN VIETNAM
HISTOPLASMOSIS - LABORATORY DIAGNOSIS IN VIETNAM National Institute of Hygiene and Epidemiology, Hanoi, Vietnam, National Institute of Infectious Diseases, Tokyo, Japan, Bach Mai hospital, Vietnam, Military
More informationEpidemiology of Cryptococcosis and Cryptococcal Meningitis in a large retrospective cohort of patients after solid organ transplantation
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2017 Epidemiology of Cryptococcosis and Cryptococcal Meningitis in a large retrospective cohort of patients after
More informationHigh-Dose Amphotericin B with Flucytosine for the Treatment of Cryptococcal Meningitis in HIV-Infected Patients: A Randomized Trial
MAJOR ARTICLE HIV/AIDS High-Dose Amphotericin B with Flucytosine for the Treatment of Cryptococcal Meningitis in HIV-Infected Patients: A Randomized Trial Tihana Bicanic, 1,4 Robin Wood, 1 Graeme Meintjes,
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationReview Article Correlation between Clinical Characteristics and Chest Computed Tomography Findings of Pulmonary Cryptococcosis
Pulmonary Medicine Volume 2015, Article ID 703407, 7 pages http://dx.doi.org/10.1155/2015/703407 Review Article Correlation between Clinical Characteristics and Chest Computed Tomography Findings of Pulmonary
More informationEarly versus Delayed Initiation of Antiretroviral Therapy for Concurrent HIV Infection and Cryptococcal Meningitis in Sub-Saharan Africa
HIV/AIDS MAJOR ARTICLE Early versus Delayed Initiation of Antiretroviral Therapy for Concurrent HIV Infection and Cryptococcal Meningitis in Sub-Saharan Africa Azure T. Makadzange, 1,3 Chiratidzo E. Ndhlovu,
More informationPulmonary Cryptococcosis in an HIV-infected Patient
Case Report Vol. 28 No. 3 Pulmonary Cryptococcosis:- Wongkulab P, et al. 203 Pulmonary Cryptococcosis in an HIV-infected Patient Panuwat Wongkulab, M.D., Nontakan Nuntachit, M.D., Romanee Chaiwarith, M.D.,
More informationMENINGITIS CRYPTOCOCCAL. learn about the symptoms, diagnosing and treating this disease
CRYPTOCOCCAL MENINGITIS learn about the symptoms, diagnosing and treating this disease A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS JANAURY 2007 Cryptococcal
More informationInfected Ventriculoperitoneal Shunt Due to Cryptococcus neoformans: the Case Report
CASE REPORT Vol. 31 No. 3 Infected ventriculoperitoneal shunt due to Cryptococcus neoformans:- Dhissayakamol O & Suankratay C. 181 Infected Ventriculoperitoneal Shunt Due to Cryptococcus neoformans: the
More informationDENGUE WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT
DENGUE WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT Usa Thisyakorn and Chule Thisyakorn Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Abstract. Dengue has spread
More informationEMA Pediatric Web Synopsis Protocol A November 2011 Final PFIZER INC.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationA retrospective review of paediatric. cryptococcosis in three academic. hospitals in Johannesburg,
A retrospective review of paediatric cryptococcosis in three academic hospitals in Johannesburg, 2002-2011. Fikile Cynthia Mabena A dissertation submitted to the Faculty of Health Sciences, University
More informationPractice Guidelines for the Management of Patients with Blastomycosis
679 Practice Guidelines for the Management of Patients with Blastomycosis Stanley W. Chapman, 1 Robert W. Bradsher, Jr., 2 G. Douglas Campbell, Jr., 3 Peter G. Pappas, 4 and Carol A. Kauffman 5 From the
More informationHIV/AIDS CLINICAL CARE QUALITY MANAGEMENT CHART REVIEW CHARACTERISTICS OF PATIENTS FACTORS ASSOCIATED WITH IMPROVED IMMUNOLOGIC STATUS
HIV/AIDS CLINICAL CARE QUALITY MANAGEMENT CHART REVIEW CHARACTERISTICS OF PATIENTS WITH LOW CD4 COUNTS IN 2008 AND FACTORS ASSOCIATED WITH IMPROVED IMMUNOLOGIC STATUS FROM 2004 THROUGH 2008 For the Boston
More informationOutline. Cryptococcosis Pneumocystosis Diarrhea. Case Histories: HIV Related- Opportunistic Infections in 2015
AU Edited: 05/06/15 Case Histories: HIV Related- Opportunistic Infections in 2015 Henry Masur, MD Clinical Professor of Medicine George Washington University School of Medicine Bethesda, Maryland Washington,
More informationRecurrent cryptococcal immune reconstitution inflammatory syndrome in an HIV-infected patient after anti-retroviral therapy: a case report
Hu et al. Annals of Clinical Microbiology and Antimicrobials 2013, 12:40 CASE REPORT Open Access Recurrent cryptococcal immune reconstitution inflammatory syndrome in an HIV-infected patient after anti-retroviral
More informationP Mwaba, J Mwansa, C Chintu, J Pobee, M Scarborough, S Portsmouth, A Zumla
Postgrad Med J 2001;77:769 773 769 Medicine and the P Mwaba Pathology and Microbiology, University Teaching Hospital, Lusaka, Zambia J Mwansa C Chintu Medicine, University J Pobee London Hospitals Trust,
More informationOpportunistic infections in the era of cart, still a problem in resource-limited settings
Opportunistic infections in the era of cart, still a problem in resource-limited settings Cristiana Oprea Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania Assessment
More informationTreatment outcomes in HIV/tuberculosis co-infected patients with CD4 cell counts < 200 cells/mm 3 and 200 cells/mm 3
Original Article Vol. 29 No. 2 Treatment outcomes in HIV/TB co-infection:- Rattanamaneekorn S & Sungkanuparph S. 5 Treatment outcomes in HIV/tuberculosis co-infected patients with CD4 cell counts < 200
More informationCryptococcal. meningitis
274 PRACTICAL NEUROLOGY REVIEW Cryptococcal meningitis Pract Neurol: first published as 10.1111/j.1474-7766.2004.00254.x on 1 October 2004. Downloaded from http://pn.bmj.com/ Jeremy N Day Clinical Research
More informationEnzyme Immunoassay versus Latex Agglutination Cryptococcal Antigen Assays in Adults With non-hiv-related Cryptococcosis
JCM Accepts, published online ahead of print on 24 September 2014 J. Clin. Microbiol. doi:10.1128/jcm.02017-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9
More informationActive TB in HIV-infected children in Thailand: Prevalence, incidence and mortality
O_17 Active TB in HIV-infected children in Thailand: Prevalence, incidence and mortality N. Salvadori 1, P. Riyaten 1, S. Thongsak 1, S. Chalermpantmetagul 1, P. Traisathit 1,2, C. Ngampiyaskul 3, S. Hanpinitsak
More informationA Case of Cryptococcal Meningitis
A Case of Cryptococcal Meningitis DOUGLAS FISH ALBANY MEDICAL COLLEGE JUNE 4, 2013 History Patient transferred from Columbia Memorial Hospital with lethargy, shortness of breath, chest pains and failure
More informationCryptococcosis*,** *usually considered to be an opportunistic mycosis that often becomes systemic.
Cryptococcosis*,** Definition - a chronic, subacute or rarely acute pulmonary, systemic or meningitic infection caused by Cryptococcus neoformans - the encapsulated Blastomycetes anamorph of Filobasidiella
More informationand the Working Group from the EMBO-AIDS Related Mycoses Workshop Institute of Infectious Disease and Molecular Medicine, University of Cape Town,
1 AIDS-related mycoses: the way forward Gordon D. Brown 1,2*, Graeme Meintjes 1, Jay K. Kolls 3, Clive Gray 1, William Horsnell 1 and the Working Group from the EMBO-AIDS Related Mycoses Workshop 1 Institute
More informationCryptococcus gattii Fungal Meningitis. By Cassy Hedberg BI 234
Cryptococcus gattii Fungal Meningitis By Cassy Hedberg BI 234 This disease s deadliest weapon is the fact you ve never heard of it -Kausik Datta, Post-doctoral Fellow at Johns Hopkins Medicine A deadly
More informationHIV-HBV coinfection in HIV population horizontally infected in early childhood between
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE HIV-HBV coinfection in HIV population horizontally infected in early childhood between 1987-1990 Supervising professor: Prof. Cupşa Augustin
More informationEvaluation of Predictive CD4 Count and Clinical Reliability in Detecting Cryptococcus neoformans at Kenyatta National Hospital, Kenya
Journal of Agriculture, Pure and Applied Science and Technology ISSN 2073-8749 Printed by Moi University Press 2009 J. agric. pure appl. sci. technol. www.japast.scriptmania.com Evaluation of Predictive
More informationHuman Immunodeficiency Virus and Leprosy Co-infection from Pune, India
JCM Accepts, published online ahead of print on 22 July 2009 J. Clin. Microbiol. doi:10.1128/jcm.00876-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationWhat is IRIS Types Outline of Presentation Principles behind Case definition of IRIS IRIS cause of early mortality IRIS a factor in optimal timing of
Immune Reconstitution Inflammatory Syndrome: A factor in Timing of Initiation of ART Yunus Moosa UKZN Durban South Africa What is IRIS Types Outline of Presentation Principles behind Case definition of
More informationDidactic Series. Fungal Infections: small bother to big mortality
Didactic Series Fungal Infections: small bother to big mortality Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 8/8/13 ACCREDITATION STATEMENT: University of California,
More informationClinical Infectious Diseases Advance Access published July 23, 2014
Clinical Infectious Diseases Advance Access published July 23, 2014 1 The Effect of Therapeutic Lumbar Punctures on Acute Mortality from Cryptococcal Meningitis Melissa A. Rolfes 1, Kathy Huppler Hullsiek
More informationPredictors of outcome in Cryptococcus neoformans var. gattii meningitis
Q J Med 1996; 89:423-428 Predictors of outcome in Cryptococcus neoformans var. gattii meningitis R.A. SEATON 1 ' 2, S. NARAQI 2, J.P. WEMBRI 2 and D.A. WARRELL 1 From f/ie 1 Centre for Tropical Medicine,
More informationGAFFI Fact Sheet. Disseminated histoplasmosis
F GAFFI Fact Sheet Disseminated histoplasmosis ION NS ACT ALOR ECTIO B O F F L G ND L IN FU NGA FU Disseminated histoplasmosis is a sub- acute infection that may be diagnosed in patients with impaired
More information14-ID-07. Standardized Surveillance Case Definition for Cryptococcus gattii infection
14-ID-07 Committee: Infectious Disease Title: tandardized urveillance Case Definition for Cryptococcus gattii infection I. tatement of the Problem Cryptococcal infections are caused by the environmentally
More informationA Child with Cross Eye. Nia Kurniati
A Child with Cross Eye Nia Kurniati Background When dealing with new case with potential social problem, complication related to ARV treatment may pose difficulties Restricted resource to address potential
More informationEXTRA-PULMONARY TUBERCULOSIS AT A REGIONAL HOSPITAL IN THAILAND
EXTRA-PULMONARY TUBERCULOSIS AT A REGIONAL HOSPITAL IN THAILAND Tawatchai Wiwatworapan and Tanakorn Anantasetagoon Chest Unit, Department of Internal Medicine, Maharat Nakhon Ratchasima Hospital, Nakhon
More informationPrevalence of cryptococcosis among HIV-infected patients in Yaounde, Cameroon
Prevalence of cryptococcosis among HIV-infected patients in Yaounde, Cameroon * Dzoyem JP 1, Kechia FA 2, Ngaba GP 3, Lunga PK 1, Lohoue PJ 2 1. Faculty of Science, University of Dschang, Cameroon. 2.
More informationToo Competent for Cryptococcus Starr Steinhilber, MD Victoria Johnson, MD
SGIM Clinical Vignettes Session F May 12, 2012 Too Competent for Cryptococcus Starr Steinhilber, MD Victoria Johnson, MD 48 yo healthy AAM Sx Fevers Chills Headache Back pain Vomiting Headache Back pain
More informationCryptococcal meningitis and SLE: a diagnostic and therapeutic challenge
CASO CLÍNICO Cryptococcal meningitis and SLE: a diagnostic and therapeutic challenge Khairullah S 1, Sulaiman H 1, Yahya F 1, Jasmin R 1, Cheah TE 1, Sockalingam S 1, Bick J 1, Chin Teck NG 1 ACTA REUMATOL
More informationImpact of Infectious Diseases Consultation on Mortality of Cryptococcal Infection in Patients Without HIV
Clinical Infectious Diseases MAJOR ARTICLE Impact of Infectious Diseases Consultation on Mortality of Cryptococcal Infection in Patients Without HIV Andrej Spec, 1 Margaret A. Olsen, 1 Krunal Raval, 1,2
More informationScreening of Hepatitis B Virus Infection among HIV- Infected Patients Receiving Antiretroviral Therapy
Original Article Vol. 27 No. 2 Screening of hepatitis B virus infection:- Chotiprasitsakul D, et al. 69 Screening of Hepatitis B Virus Infection among HIV- Infected Patients Receiving Antiretroviral Therapy
More informationChallenges in diagnosis and management of Cryptococcal immune reconstitution inflammatory syndrome (IRIS) in resource limited settings
Challenges in diagnosis and management of Cryptococcal immune reconstitution inflammatory syndrome (IRIS) in resource limited settings Musubire AK 1, Meya BD 1,2,3, Mayanja-Kizza H 3, Lukande R 4, Wiesner
More informationCase Presentation. Intern Tutor VS 2007/01/26
Case Presentation Intern 8931150 Tutor VS 2007/01/26 About The Patient 38 years old worker ID: M120794700 Admission date: 2006/12/28 C.C.: Fever with headache for 2 days Present Illness Smoker, alcoholism
More informationCASE REPORT. Abstract. Introduction. Case Report
CASE REPORT Disseminated Cryptococcosis Complicated with Bilateral Pleural Effusion and Ascites during Corticosteroid Therapy for Organizing Pneumonia with Myelodysplastic Syndrome Hiroyuki Kamiya 1, Rie
More informationLecture 7: Mycoses Caused by Dimorphic Fungi, Part I
BIOL 4849 Medical Mycology Summer 2006 Histoplasmosis Lecture 7: Mycoses Caused by Dimorphic Fungi, Part I u Most common endemic mycotic disease in the United States u Two different varieties (actually
More informationStudy of systemic fungal infections in renal transplant recipients
Original Research Article Study of systemic fungal infections in renal transplant recipients N.D. Srinivasaprasad 1*, G. Chandramohan 1, M. Edwin Fernando 2 1 DM (Nephrology), Assistant Professor, 2 DM
More informationSupervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles
I Congreso de GESIDA Madrid, 21-24 de Octubre del 2009. Supervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles José M. Miró, 1 Miguel Montejo,
More informationThis PDF is available for free download from a site hosted by Medknow Publications. (www.medknow.com).
Review Article Cryptococcal meningitis: Clinical, diagnostic and therapeutic overviews P. Satishchandra, T. Mathew, G. Gadre, S. Nagarathna, A. Chandramukhi*, A. Mahadevan**, S. K. Shankar** Department
More informationAetiology of meningitis at the Moi Teaching and Referral Hospital, Eldoret, Kenya. D. K. Lagat, MBChB, Mmed(Moi)
Aetiology of meningitis at the Moi Teaching and Referral Hospital, Eldoret, Kenya D. K. Lagat, MBChB, Mmed(Moi) Introduction Meningitis is common and important Syndromes of meningitis: Acute bacterial
More informationGeneral History. 林陳 珠 Female 69 years old 住院期間 : ~ Chief Complaint : sudden loss of conscious 5 minutes in the morning.
General History 林陳 珠 Female 69 years old 住院期間 : 93.5.8~93.5.15 Chief Complaint : sudden loss of conscious for 2-52 5 minutes in the morning. General History DM under regular medical control for 10 years.
More informationOpportunistic Infections BHIVA Guidelines
Opportunistic Infections BHIVA Guidelines Mark Nelson David Dockrell Simon Edwards I have.. 1. Read all of the BHIVA guidelines 12% 2. Read some of the BHIVA guidelines in their entirety 3. Browsed some
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationTakashi Yuri, Ayako Kimura, Katsuhiko Yoshizawa, Yuko Emoto, Yuichi Kinoshita, and Airo Tsubura
Case Reports in Pathology Volume 2013, Article ID 807197, 4 pages http://dx.doi.org/10.1155/2013/807197 Case Report Pulmonary and Meningeal Cryptococcosis after Corticosteroid Therapy for Autoimmune Hepatitis:
More informationTREATMENT OF CRYPTOCOCCAL MENINGITIS ASSOCIATED WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME
TREATMENT OF CRYPTOCOCCAL MENINGITIS ASSOCIATED WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME CHARLES M. VAN DER HORST, M.D., MICHAEL S. SAAG, M.D., GRETCHEN A. CLOUD, M.S., RICHARD J. HAMILL, M.D., J. RICHARD
More informationMay He Rest in Peace
May He Rest in Peace Neurologic Complications of AIDS Medical Knowledge Fiesta 2012 Paul K. King MD pkingmd@yahoo.com Objectives definition of HIV/AIDS what are the neurologic complications of AIDS how
More informationHISTOPLASMOSIS AND PENICILLIOSIS AMONG HIV- INFECTED THAI PATIENTS: A RETROSPECTIVE REVIEW
Southeast Asian J Trop Med Public Health HISTOPLASMOSIS AND PENICILLIOSIS AMONG HIV- INFECTED THAI PATIENTS: A RETROSPECTIVE REVIEW Fatima Rangwala 1, Opass Putcharoen 2, Chureeratana Bowonwatanuwong 3,
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationReasons why we will never forget. Andrea Antinori INMI L. Spallanzani IRCCS, Roma
Reasons why we will never forget Andrea Antinori INMI L. Spallanzani IRCCS, Roma SMRs according to time spent with CD4 count >500/mm3 after cart initiation in MSM 80,642 HIV-infected individuals eligible
More informationManagement of cryptococcal meningitis in HIVinfected patients: Experience from western India
Original Article Management of cryptococcal meningitis in HIVinfected patients: Experience from western India Atul K. Patel, Ketan K. Patel, Rajiv Ranjan, Shalin Shah 2, Jagdish K. Patel 1 Infectious Diseases
More information